Accendra Health, Inc. is a U.S. provider of home healthcare equipment, medical supplies, and related services. The company operates through its Apria and Byram Healthcare brands, offering products and support for diabetes treatment, home respiratory therapy, obstructive sleep apnea, wound care, urology, and ostomy care. It serves patients, home health agencies, and providers, with payments received from Medicare, Medicaid, private insurers, and direct patient payments. Accendra Health utilizes technology for electronic ordering, claims submission, and funds transfer to streamline administrative processes. The company formerly operated as Owens & Minor, Inc. and completed the sale of its Products & Healthcare Services business in December 2025, retaining a minority equity interest in the sold entity.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Distribution Homepage accendrahealth.com
Sector Healthcare IR page investors.accendrahealth.com
Tags
home healthcare, durable medical equipment, respiratory therapy, diabetes care, wound care, ostomy care, urology, sleep apnea treatment, medical supplies, patient support services, Apria, Byram Healthcare, Lofta
Press page —

Metrics

Valuation  
Market cap $ 43.285M
Market cap (USD) $ 43.285M
P/E -0.42
PEG —
P/BV -0.08
P/S 0.02
P/OCF -1.71
P/FCF -0.15
Dividend yield 1.8%
Turnover / mcap —
Returns  
ROE 238.8%
ROI —
ROIC —
Profit margin -39.8%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 44
Quality score -62.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 2.762B 10.701B 10.334B 9.955B 9.785B 8.48B 9.211B 9.839B 9.318B 9.723B 9.773B 9.44B 9.072B 8.908B 8.628B 8.124B 8.038B 7.243B 6.8B 5.534B — — 4.244B 3.96B 3.815B 3.504B
Net profit -1.101B -362.686M -41.301M 22.389M 221.589M 29.871M -62.371M -437.012M 72.793M 108.787M 103.409M 66.503M 110.882M 109.003M 115.198M 110.579M 104.658M 93.327M — — — — 53.641M 47.267M 23.035M 33.088M
Free cash flow -292.746M -49.37M 549.84M 166.916M 83.192M 288.799M 123.666M 70.716M 22.161M 166.632M 249.066M -52.185M 112.435M 208.674M 43.438M 213.362M 145.574M 45.209M 199.756M -95.528M 105.208M 45.401M 88.307M -19.077M -8.506M 35.15M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 2.8 13.07 19.27 19.53 43.5 27.05 5.17 6.33 18.88 35.29 35.98 35.11 36.56 28.51 27.9 29.43 42.99 — — — — — — — — —
Price performance 12m -0.79 -0.32 -0.01 -0.55 0.61 4.23 -0.18 -0.66 -0.47 -0.02 0.02 -0.04 0.28 0.02 -0.05 -0.32 — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) 4.8M 16.6M 30.6M 51.2M 39.9M — 17.9M 207M 45.5M 250M
Borrowings, non-current (USD) 565M 901M 1.65B 1.51B 986M 948M 2.48B 1.89B 1.81B 1.8B
Lease liabilities (USD) — — 0.00 161M 165M 217M 307M 320M 387M 114M
Cash and deposits (USD) 185M 105M 103M 67M 83.1M 55.7M 69.5M 243M 49.4M 282M
Intangible assets (USD) 82.5M 184M 322M 285M 243M 210M 445M 362M 299M 136M
Right-of-use assets (USD) — — 0.00 142M 145M 194M 281M 297M 356M 109M
Net debt (borrowings + leases - cash) (USD) 384M 813M 1.58B 1.65B 1.11B 1.11B 2.72B 2.17B 2.19B 1.88B
Cash flow detail
Operating cash flow (USD) 187M 56.8M 116M 166M 339M 124M 325M 741M 161M -102M
Purchases of property, plant and equipment (USD) -20.3M -34.6M -44.9M -42.4M -50.4M -41M -158M -191M -211M -191M
Purchases of intangible assets (USD) -9.82M -16.1M -20.8M -9.81M -8.77M -8.71M -8.49M -17M -17.3M -10.4M
Change in receivables (cash effect) (USD) -25.2M -100M 11.1M 63.5M -34.8M -2.2M 1.1M 167M -94.6M 122M
Change in inventories (cash effect) (USD) 22.6M -57M -65.5M 128M -85.2M -263M 167M 224M -26.2M -6.85M
Dividends paid (cash effect) (USD) -63.4M -63.2M -48.2M -5.23M -648,000 -731,000 0.00 0.00 — —
Share buybacks (cash effect) (USD) -71M -5M 0.00 — — — — — — -10.2M
Interest paid (cash effect) (USD) -27.9M -30.6M -68.6M -95.4M -90M -38.7M -107M -153M -142M -135M
Income taxes paid (cash effect) (USD) -74.1M -41.8M -28.9M 6.2M 17.5M -99.4M -34M 6.28M -5.55M -12.5M
Share-based compensation (USD) 12M 11.9M 16.4M 15.8M 20M 25M 21M 23.2M 26.8M 12.9M
Operating cash flow before change in receivables (USD) 212M 157M 104M 103M 374M 126M 324M 574M 256M -224M
Free cash flow (OCF - PPE - intangibles) (USD) 157M 6.04M 49.9M 114M 280M 74.5M 158M 533M -66.7M -303M
Income detail
Research and development expense (USD) — — — — — 12.1M 11.8M 13.2M 13M —
Total comprehensive income (USD) 93.1M 115M -458M -69.5M 44.1M 220M 27.1M -37.3M -380M -1.05B
Comprehensive income to owners (USD) 93.1M 115M -458M -69.5M 44.1M 220M 27.1M -37.3M -380M -1.05B
Provision for credit losses (USD) 377,000 2.67M 9.43M 12.9M 11.3M 21.2M 3.32M -1.41M — —
Reported Feb 17, 2017 Feb 23, 2018 Nov 6, 2019 Mar 4, 2020 Feb 24, 2021 Feb 20, 2024 Feb 20, 2024 Feb 20, 2024 Feb 28, 2025 Feb 20, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Trading Will Continue on the Over-the-Counter Market Under Ticker Symbol “ACCH”

RICHMOND, Va., November 17, 2026 -- Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced that it received notification from the New York Stock Exchange (“NYSE”) on November 16, 2026, informing it that trading of the Company’s common stock on the NYSE was suspended, effective immediately, and that the NYSE has determined to commence proceedings to delist the Company’s common stock. The NYSE reached its decision to delist the Company’s common stock pursuant to Rule 802.01D of the NYSE Listed Company Manual, based on abnormally low selling price levels.

The Company’s common stock began trading on the OTCQB market under the ticker symbol “ACCH” on November 17, 2026. This transition to the over-the-counter market will not affect the Company’s business operations or its U.S. Securities and Exchange Commission reporting obligations, and it does not conflict with or cause an event of default under any of the Company’s material debt or other agreements.

RICHMOND, VA – November 5, 2026 – Accendra Health, Inc. (NYSE: ACH) (the Company) today reported financial results for the third quarter ended September 30, 2026. Unless otherwise noted, the results herein reflect the Company’s continuing operations, which represent what was previously the Patient Direct segment and certain functional operations.

“Over the several weeks since I started, a number of themes have become clear to me. We have strong brands, favorable end markets, and a teammate population dedicated to our mission, Bringing Care To Life. It is equally clear to me that our results to date in 2026 have fallen well short of our expectations and potential. We have identified four key areas which are critical to our continued transformation and returning the business to the kind of profitability that our shareholders should expect” said Kenny Gardner-Smith, President & Chief Executive Officer, Accendra Health.

“We are already taking action on our turnaround, and, over the next several months, we will have our value creation plan fully underway.

October 30, 2026

RICHMOND, Va.--(BUSINESS WIRE)-- Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that on October 27, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with Section 802.01B of the NYSE’s continued listing standards that the Company have an average market capitalization of not less than $50.0 million over a consecutive 30 trading-day period and stockholders’ equity of not less than $50.0 million. The Notice does not result in the immediate delisting of the Company’s Class A Common Stock (the “Common Stock”) from the NYSE.

The Company intends to respond to the NYSE within ten business days of receipt of the Notice affirming its intent to submit a business plan. Pursuant to Section 802.01B, the Company has a period of 45 calendar days following receipt of the Notice to submit a business plan that demonstrates how the Company intends to regain compliance with Section 802.01B within 18 months of receipt of the Notice. The NYSE will review the business plan and, if accepted, the Company will be subject to quarterly monitoring by the NYSE of the progress of the business plan.

​​The Company’s Common Stock will continue to be listed and trade on the NYSE during this period, subject to its compliance with other NYSE continued listing standards. The receipt of the Notice does not affect the Company’s business, operations or reporting requirements with the Securities and Exchange Commission.

Safe Harbor

This release is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the SEC’s Fair Disclosure Regulation. This release contains certain “forward looking” statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the Company’s ability to maintain the listing of its Common Stock on the NYSE, its intentions regarding regaining compliance with the NYSE’s continued listing standards, including the submission and acceptance of a business plan, its ability to create shareholder value, and stock price expectations, as well as the Company’s anticipated future prospects and performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements. Investors should refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 20, 2026, including the section captioned “Item 1A. Risk Factors,” as applicable, and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with or furnished to the SEC, for a discussion of certain known risk factors that could cause the Company’s actual results to differ materially from its current estimates. These filings are available at www.accendrahealth.com . Given these risks and uncertainties, the Company can give no assurance that any forward-looking statements will, in fact, transpire and, therefore, cautions investors not to place undue reliance on them. The Company specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

About Accendra Health

Accendra Health, Inc. (NYSE: ACH) is a leading nationwide provider of products, technology, and services that support health beyond the hospital for millions of people each year. We connect patients, providers, and insurers, delivering innovative solutions that help promote better health outcomes and improve quality of life for people living with chronic, complex health conditions. Backed by the industry-leading expertise of our Apria and Byram brands, Accendra Health is reimagining the future of home-based care. To learn more about our broad portfolio of essentials for diabetes, sleep health, wound care, respiratory care, urology, and ostomy, visit www.accendrahealth.com .

​ACH-CORP
ACH-IR

Investors
Will Parrish
Vice President, Strategy, Corporate Development, & Investor Relations
[email protected]

​Media
Darla Turner
[email protected]

Source: Accendra Health, Inc.

View All News

Prompts

Accendra Health, Inc. (ticker ACH), listed in United States.

Company History

Date Change Detail
Jan 5, 2026 Renamed OWENS & MINOR INC/VA/ → ACCENDRA HEALTH INC/VA/
Sep 30, 2014 Acquired Acquired Medical Action Industries Inc (CIK 748270). Its filings from before the deal are on its own company page, not shown here.
— Former tickers OMI

ETFs Holding Accendra Health, Inc.

ETF Weight in ETF Shares Market value As of
QIDX 0.11% 14,310 $ 44.218K Jul 31, 2026
VFVA 0.05% 426,785 $ 516.41K Aug 31, 2026
DFSV 0.00% 373,635 $ 54.551K Nov 12, 2026
DFAT 0.00% 351,217 $ 51.278K Nov 12, 2026
DFAS 0.00% 24,382 $ 3,559.77 Nov 12, 2026